[1] [1] CRICK F H. Thinking about the brain［J］. Scientific American, 1979, 241(3): 219-232.

[2] [2] ZEMELMAN B V, LEE G A, NG M, et al. Selective photostimulation of genetically chARGed neurons［J］. Neuron, 2002, 33(1): 15-22.

[3] [3] BOYDEN E S, ZHANG F, BAMBERG E, et al. Millisecond-timescale, genetically targeted optical control of neural activity［J］. Nature Neuroscience, 2005, 8(9): 1263-1268.

[4] [4] DEISSEROTH K, FENG G, MAJEWSKA A K, et al. Next-generation optical technologies for illuminating genetically targeted brain circuits［J］. Journal of Neuroscience, 2006, 26(41): 10380-10386.

[5] [5] DUEBEL J, MARAZOVA K, SAHEL J A. Optogenetics［J］. Current Opinion in Ophthalmology, 2015, 26(3): 226-232.

[6] [6] ZHANG F, VIEROCK J, YIZHAR O, et al. The microbial opsin family of optogenetic tools［J］. Cell, 2011, 147(7): 1446-1457.

[7] [7] OESTERHELT D, STOECKENIUS W. Rhodopsin-like protein from the purple membrane of Halobacterium halobium［J］. Nature: New Biology, 1971, 233(39): 149-152.

[8] [8] OESTERHELT D, STOECKENIUS W. Functions of a new photoreceptor membrane［J］. Proceedings of the National Academy of Sciences of the United States of America, 1973, 70(10): 2853-2857.

[9] [9] MATSUNO-YAGI A, MUKOHATA Y. Two possible roles of bacteriorhodopsin; a comparative study of strains of Halobacterium halobium differing in pigmentation［J］. Biochemical and Biophysical Research Communications, 1977, 78(1): 237-243.

[10] [10] SCHOBERT B, LANYI J K. Halorhodopsin is a light-driven chloride pump［J］. The Journal of Biological Chemistry, 1982, 257(17): 10306-10313.

[11] [11] NAGEL G, OLLIG D, FUHRMANN M, et al. Channelrhodopsin-1: a light-gated proton channel in green algae［J］. Science, 2002, 296(5577): 2395-2398.

[12] [12] TYE K M, DEISSEROTH K. Optogenetic investigation of neural circuits underlying brain disease in animal models［J］. Nature Reviews: Neuroscience, 2012, 13(4): 251-266.

[13] [13] NAGEL G, SZELLAS T, HUHN W, et al. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel［J］. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(24): 13940-13945.

[14] [14] GOVORUNOVA E G, SINESHCHEKOV O A, LI H, et al. Characterization of a highly efficient blue-shifted channelrhodopsin from the marine alga Platymonas subcordiformis［J］. Journal of Biological Chemistry, 2013, 288(41): 29911-29922.

[15] [15] WEN L, WANG H, TANIMOTO S, et al. Opto-current-clamp actuation of cortical neurons using a strategically designed channelrhodopsin［J］. PLoS One, 2010, 5(9): e12893.

[16] [16] YIZHAR O, FENNO L E, PRIGGE M, et al. Neocortical excitation/inhibition balance in information processing and social dysfunction［J］. Nature, 2011, 477(7363): 171-178.

[17] [17] LIN J Y, KNUTSEN P M, MULLER A, et al. ReaChR: a red-shifted variant of channelrhodopsin enables deep transcranial optogenetic excitation［J］. Nature Neuroscience, 2013, 16(10): 1499-1508.

[18] [18] KLAPOETKE N C, MURATA Y, KIM S S, et al. Independent optical excitation of distinct neural populations［J］. Nat Methods, 2014, 11(3): 338-346.

[19] [19] WANG H, SUGIYAMA Y, HIKIMA T, et al. Molecular determinants differentiating photocurrent properties of two channelrhodopsins from chlamydomonas［J］. Journal of Biological Chemistry, 2009, 284(9): 5685-5696.

[20] [20] LIN J Y, LIN M Z, STEINBACH P, et al. Characterization of engineered channelrhodopsin variants with improved properties and kinetics［J］. Biophysical Journal, 2009, 96(5): 1803-1814.

[21] [21] GUZIK A, BUSHNELL C. Stroke epidemiology and risk factor management［J］. Continuum (Minneap Minn), 2017, 23(1): 15-39.

[22] [22] FLOEL A, COHEN L G. Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke［J］. Neurobiology of Disease, 2010, 37(2): 243-251.

[23] [23] LU C, WU X, MA H, et al. Optogenetic stimulation enhanced neuronal plasticities in motor recovery after ischemic stroke［J］. Neural Plasticity, 2019, 2019: 5271573.

[24] [24] SHAH A M, ISHIZAKA S, CHENG M Y, et al. Optogenetic neuronal stimulation of the lateral cerebellar nucleus promotes persistent functional recovery after stroke［J］. Scientific Reports, 2017, 7: 46612.

[25] [25] TYSNES O B, STORSTEIN A. Epidemiology of Parkinson’s disease［J］. Journal?of?Neural?Transmission (Vienna), 2017, 124(8): 901-905.

[26] [26] MILLER D B, O’CALLAGHAN J P. Biomarkers of Parkinson’s disease: present and future［J］. Metabolism: Clinical and Experimental, 2015, 64(3): S40-S46.

[27] [27] KRAVITZ A V, FREEZE B S, PARKER P R, et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry［J］. Nature, 2010, 466(7306): 622-626.

[28] [28] BASS C E, GRINEVICH V P, VANCE Z B, et al. Optogenetic control of striatal dopamine release in rats［J］. Journal of Neurochemistry, 2010, 114(5): 1344-1352.

[29] [29] HALLIDAY G M, DEL TREDICI K, BRAAK H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease［J］. Journal of Neural Transmission Supplementum, 2006(70): 99-103.

[30] [30] BRAAK H, DEL TREDICI K, RüB U, et al. Staging of brain pathology related to sporadic Parkinson’s disease［J］. Neurobiology of Aging, 2003, 24(2): 197-211.

[31] [31] VAZEY E M, ASTON-JONES G. The emerging role of norepinephrine in cognitive dysfunctions of Parkinson’s disease［J］. Frontiers in Behavioral Neuroscience, 2012, 6: 48.

[32] [32] THIJS R D, SURGES R, O’BRIEN T J, et al. Epilepsy in adults［J］. Lancet, 2019, 393(10172): 689-701.

[33] [33] YE H, KASZUBA S. Inhibitory or excitatory? Optogenetic interrogation of the functional roles of GABAergic interneurons in epileptogenesis［J］. Journal of Biomedical Science, 2017, 24(1): 93.

[34] [34] MOOSA A N V. Antiepileptic drug treatment of epilepsy in children［J］. Continuum (Minneap Minn), 2019, 25(2): 381-407.

[35] [35] ZHAO M, ALLEVA R, MA H, et al. Optogenetic tools for modulating and probing the epileptic network［J］. Epilepsy Research, 2015, 116: 15-26.

[36] [36] TONNESEN J, SORENSEN A T, DEISSEROTH K, et al. Optogenetic control of epileptiform activity［J］. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(29): 12162-12167.

[37] [37] SUKHOTINSKY I, CHAN A M, AHMED O J, et al. Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model［J］. PLoS One, 2013, 8(4): e62013.

[38] [38] SELVARAJ P, SLEIGH J W, FREEMAN W J, et al. Open loop optogenetic control of simulated cortical epileptiform activity［J］. Journal of Computational Neuroscience, 2014, 36(3): 515-525.

[39] [39] HERNANDEZ V H, GEHRT A, REUTER K, et al. Optogenetic stimulation of the auditory pathway［J］. Journal of Clinical Investigation, 2014, 124(3): 1114-1129.

[40] [40] STRA?áK Z, KOUSAL B, ARDAN T, et al. Innovative strategies for treating retinaldiseases［J］. Ceska a Slovenska Oftalmologie, 2020, 75(6): 287-295.

[41] [41] BISELLI T, LANGE S S, SABLOTTNY L, et al. Optogenetic and chemogenetic insights into the neurocircuitry of depression-like behaviour: a systematic review［J］. European Journal of Neuroscience, 2021, 53(1): 9-38.

[42] [42] JARRIN S, FINN D P. Optogenetics and its application in pain and anxiety research［J］. Neuroscience and Biobehavioral Reviews, 2019, 105: 200-211.